Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Netscientific Plc | NSCI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 53.50 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 53.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 26/9/2024 06:58 by loafofbread NetScientific plc("NetScientific" or the "Company") Name change and AIM Rule 26 website NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, is pleased to announce that it has changed its name to "EMV Capital plc". Regulatory information concerning the Company's name change The Company was issued by Companies House with a change of name certificate on 25 September 2024 and the name change from "NetScientific plc" to "EMV Capital plc" became effective immediately upon such receipt. Similarly, the Company's wholly owned venture capital and corporate finance firm, EMV Capital Limited, has changed its name to EMV Capital Partners Limited with immediate effect. The Company confirms that its change of name has been notified to the London Stock Exchange and trading in the Company's shares under the new company name and new TIDM code, "EMVC", is expected to commence at 8.00 a.m. on 26 September 2024. The Company's ISIN and SEDOL remain unchanged. In conjunction with its name change, the Company's website address will change to emvcapital.com. All information required by Rule 26 of the AIM Rules for Companies will be located on the "Investors" section of the website with effect from 8.00 a.m. on 26 September 2024. Shareholders rights are unaffected by these changes and existing share certificates should be retained and remain valid. Background to the Company's name change and rebranding The rebranding marks the culmination of NetScientific's strategic evolution, since acquiring EMV Capital in 2020, to a fully integrated venture capital and corporate finance business. The Group has grown substantially in both scale and scope since its inception. In 2019, the Group's portfolio fair value stood at approximately £8 million. Today, through its capital-efficient model and strategic value-creation services, the Group has established itself as a key player in venture capital, spanning deep tech, life sciences, and other innovative sectors. The EMV Capital brand, used by the Group since 2020, is already highly regarded and well established in this space, and as such the name change and rebranding across the Group is a logical step towards unifying the Group's offerings to its stakeholders. EMV Capital plc now manages a diversified portfolio of over 70 companies with estimated AUM exceeding £100 million (as announced on 13 June 2024), significantly expanding beyond its origins and is uniquely positioned to leverage its expertise across fund management, corporate finance, and portfolio growth services to deliver positive returns for investors, even when market conditions remain challenging. As EMV Capital plc, the Group continues its expansion beyond life sciences into deep tech, including sectors such as sustainability, digital health, and advanced materials. The Company's ability to provide fund management, corporate finance, and syndication services across its portfolio enables it to identify, nurture, and accelerate the growth of early-stage companies. By offering hands-on support through each growth phase, EMV Capital is committed to helping companies scale while delivering meaningful societal impact. With a goal to further grow Assets Under Management, the Group aims to scale its capital-efficient investment model, expand its fund management practice, and enhance the value of its portfolio through targeted investments and value-creation services. Dr. Ilian Iliev, CEO of EMV Capital plc, commented: "Since acquiring EMV Capital in 2020, we have consolidated our operations, significantly grown our portfolio, and expanded our strategic focus. This new identity for our Group reflects our business today-an agile, multi-sector venture capital firm committed to delivering superior returns from innovative, high-growth companies. "With Assets Under Management having surpassed £100 million, this milestone highlights our success in navigating a challenging market and underscores our ambitious plans for the future. Our continued focus on deep tech and life sciences, combined with our value-creation approach, positions EMV Capital to be at the forefront of driving the next wave of innovation and shareholder value." |
Posted at 24/9/2024 21:26 by btgman Interesting comments around £2 NAV. This is really interesting down here share price has now dismissed the recent Martlet Capital deal along with some fairly significant updates from several of the portfolio.Yes £2 NAV all day long but that is hardly the story. Glycotest looks absolutely incredible within 2 years Glycotest will be worth significantly more than £2 to NSCI on its own. We have a several high upside assets in our portfolio so for me £2 isn't the number. More likely multiples of £2 AIMHO GLA BTG |
Posted at 24/9/2024 08:11 by blakieboy7 NSCI should have a legal obligation to release any relevant RNS's |
Posted at 23/9/2024 21:00 by loafofbread NSCI just refuse to issue any press that might have a positive impact on their share price!All very odd considering we hold over 50% of Glycotest. EMV CAPITAL-BACKED GLYCOTEST™ PARTNERS WITH UNIVERSITY OF GEORGIA TO ACCELERATE NOVEL LIVER CANCER DIAGNOSTIC ASSAYS SEPTEMBER 23, 2024-NEWS - NO COMMENTS - POSTED BY WEBMASTER Merion, PA – 23 September 2024 – Glycotest, Inc. announces that it has entered into an agreement with the University of Georgia Complex Carbohydrate Research Center (CCRC) in Athens, GA to develop novel glycomic assays for its HCC Panel blood test, aimed at early-stage liver cancer detection. The agreement moves Glycotest towards commercializing its breakthrough platform, leveraging significant R&D efforts to tackle Hepatocellular Carcinoma (HCC), the most common and lethal form of liver cancer. Under the terms of the agreement, Glycotest will fund the development of the new assays at the CCRC, with Glycotest securing exclusive rights to the resulting intellectual property. The new assays developed by the CCRC will be deployed by Glycotest in its HCC Panel test. The assay development work will be spearheaded by Dr. Parastoo Azadi, Associate Director of CCRC Service and Training. Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company has made huge strides in developing its innovative diagnostic technology and the deal with CCRC, a world leader in glycoscience, marks a crucial step toward market launch. Charles Swindell, PhD, CEO, Glycotest, commented: “Glycotest is fortunate to partner with the CCRC—a world renowned innovator in glycoscience testing methodology—on this final chapter in making the HCC Panel test available to liver disease patients and their physicians. We believe the HCC Panel could become a significant tool for better identification of early-stage HCC patients eligible for potentially curative therapy.” The CCRC’s expertise will enhance Glycotest’s proprietary HCC Panel, which has already shown promise in identifying early-stage liver cancer—where treatment options can be most effective. The potential market is huge, with an estimated three million patients in the US, and potentially up to 380 million patients worldwide, eligible for routine HCC surveillance testing. Glycotest employs unique non-invasive blood tests based on proprietary serum glycoprotein biomarkers, biomarker panels and assay technology that exploit novel carbohydrate-based disease signal chemistry. The CCRC is a long-standing center of excellence in the glycosciences, the branch of science that investigates the structure, biosynthesis, and biological functions of molecules that contain carbohydrates. With expertise and resources in a rich array of sophisticated instrumental techniques key to glycoscience research, the CCRC is uniquely positioned to collaborate with Glycotest on this important project focusing on the development of superior mass spectroscopy-based glycomic assays. Parastoo Azadi, PhD, Associate Director of the CCRC-Service and Training, said: “Glycomic and glycoproteomic analyses possess remarkable potential for enhancing diagnostic tests, especially in the realm of liver disease. We are eager to apply our expertise in carbohydrate analysis development in collaboration with Glycotest, aiming to innovate new glycomic and glycoproteomic methodologies for glycoprotein biomarkers.” Large Biobank Now Ready for Commercial Push Glycotest’s proprietary HCC Panel blood test, powered by novel glycoprotein biomarkers and an advanced scoring algorithm, is intended to transform liver cancer detection. Crucially, the Company has successfully completed patient enrolment and sample collection for its HCC Panel clinical validation study, carried out across 20 major medical centers under the leadership of key opinion leaders. This effort has resulted in the creation of a world-leading biobank, now one of the largest collections of blood samples globally for HCC test validation. The biobank provides a highly valuable resource to confirm the performance of Glycotest’s HCC Panel to identify early-stage, potentially curable liver cancer. About Glycotest, Inc. Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology innovated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Glycotest is backed by the London-based VC investor EMV Capital, specialising in early-stage high-growth deep tech companies, and the global pharmaceutical and healthcare industry group Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”). Learn more at [...] |
Posted at 23/9/2024 15:09 by loafofbread Some decent news out from Glycotest today. Looks like it might be worth multiple millions rather than the zero value that the NSCI share price gives it! |
Posted at 23/8/2024 09:56 by kingston78 It has looked to me for quite some time that the share price will drift to the 50 p level again. If it does, I think that should be the bottom. It may crawl along and bounce up from there. A double bottom (excuse me for the language)in charting term is good for a bounce.The trading volume is low, indicating lack of interest by both existing and new shareholders. In this regard, the company's PR is dreadful. NSCI is simply an investment company without deep pocket. It should have sold its stake in PDSB long ago when PDSB's share price was above US$14 a share but it is trading at US$3 to US$4. You cannot rely on one investment as being the "wonder stock" when it gets less appealing (with benefit of hindsight). As investors, we buy, sell or hold, and we probably take all those actions. NSCI only buys and holds, and wait for its investments to become more valuable. NSCI does not sell when its investments become more valuable (maybe getting greedy). That is a poor investor's attitude. A paper profit is not a profit until realised. This is basic investment rule. I should teach the directors some basic investment rules. |
Posted at 12/8/2024 20:21 by kingston78 When PDSB's share price was above US$12 NSCI did not sell part of its holdings. Instead it has clung onto it. PDSB is now trading at approximately US$3 a share. I think that the directors' blind faith in PDSB has cost the company dear.I really don't understand the directors' strategy. It has a mixed bag of investments but none of which is returning to it any cash. |
Posted at 06/7/2024 23:17 by kingston78 My previous summary that the company was trading at the top of its band at 79 p has been proven correct. The share price has since dropped back to 70-72 p.A wife was complaining to her friends that whilst her husband's business was doing well she did not see any improvement in their standard of living. Some years later when her husband cashed in his business they suddenly became cash millionaires. NSCI (or rather us investors)is like the wife described above. Asset rich but cash poor. Dragon's Den will ask a simple question, "show me the cash". Value may rise and value may fall. Only cash is king. As reiterated before, NSCI will only rise substantially if a large investor continues to buy its shares to push up the price, or a large profitable cash exit from one or more of its investments will pave the way upwards. Small investors have little influence. |
Posted at 26/6/2024 17:17 by kingston78 NSCI is always lightly traded, so there cannot be many followers or new investors. I think that there is a lack of promotion to the right audience.Despite MM has marked down the price by 1p today the spread has narrowed from 6p to only 1 p (72-73p). It would appear that MM wants sellers to sell them the stock, as they keep a tight book. In this respect, any pent up demand generated by, for example, an investment recommendation by IC or others, will raise the share price by a few pence. Anyway, as I have iterated before, unless and until the company has realised real cash in exiting one or more of its investments the share price will reach 90 p - 100 p at best in the next few months. If achieved, that is not a bad return. Years ago, I realised that investment trusts were mostly trading at a discount to their underlying assets whilst Unit Trusts were trading at a premium. This is a perception issue. NSCI is acting like an investment trust, investing in a number of companies that may generate a good return. I have no doubt in my mind that one day, we only need a blockbuster to increase the value of NSCI many folds. We live in hope. |
Posted at 13/6/2024 10:18 by kingston78 The important factor was that when PDSB was at a high of US$14 the share price of NSCI had hardly progressed. Subsequent events have shown that NSCI has become a more rounded investment companies with a promising portfolio of high tech companies at their early stage. Moreover, NSCI does not contribute much in cash term the advancement of those companies, which rely on external funding, which at a higher subscription price, actually adds value to NSCI despite the fact that they are unlisted. One of these days there will be a profitable exit, or exits, and investors will see that NSCI has many gems. This is akin to some people who are asset rich but cash poor.I am just concerned that NSCI will not have sufficient cash to run its corporate activities and resort to a discounted fund raising itself. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
